Karen S. Acker

Array ( [id] => 17665342 [patent_doc_number] => 11359023 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use [patent_app_type] => utility [patent_app_number] => 17/199205 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 69 [patent_no_of_words] => 32973 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17199205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793349 [patent_doc_number] => 12234279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Peptide construct having a protease-cleavable linker [patent_app_type] => utility [patent_app_number] => 17/196498 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 21120 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18279581 [patent_doc_number] => 20230095053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => ANTIBODIES COMPRISING SITE-SPECIFIC GLUTAMINE TAGS, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 17/908882 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17908882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20185943 [patent_doc_number] => 12397044 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => Method for improving the benefit to a subject of a therapy or therapeutic agent [patent_app_type] => utility [patent_app_number] => 17/191634 [patent_app_country] => US [patent_app_date] => 2021-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 50 [patent_no_of_words] => 30828 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17191634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18916734 [patent_doc_number] => 11879004 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Modified binding polypeptides for optimized drug conjugation [patent_app_type] => utility [patent_app_number] => 17/187039 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 25 [patent_no_of_words] => 32552 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036707 [patent_doc_number] => 20210253665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/181913 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885424 [patent_doc_number] => 20210171619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => NOVEL ANTIBODY FORMAT [patent_app_type] => utility [patent_app_number] => 17/177543 [patent_app_country] => US [patent_app_date] => 2021-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22003 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17177543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19291580 [patent_doc_number] => 12030926 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-09 [patent_title] => Production of heteromultimeric proteins using mammalian cells [patent_app_type] => utility [patent_app_number] => 17/171962 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 40815 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082085 [patent_doc_number] => 20210277091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 17/163618 [patent_app_country] => US [patent_app_date] => 2021-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853518 [patent_doc_number] => 20210154263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/152111 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050679 [patent_doc_number] => 20210260113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => DEVICES, METHODS, COMPOSITIONS AND SYSTEMS FOR THE TREATMENT OF AGING AND AGE-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/150466 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 130757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022325 [patent_doc_number] => 20210246196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS [patent_app_type] => utility [patent_app_number] => 17/150005 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076512 [patent_doc_number] => 11945862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Compositions and methods for antibody production [patent_app_type] => utility [patent_app_number] => 17/147743 [patent_app_country] => US [patent_app_date] => 2021-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 32 [patent_no_of_words] => 23028 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948160 [patent_doc_number] => 20210206851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => LAG-3-Binding Molecules and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/147279 [patent_app_country] => US [patent_app_date] => 2021-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41048 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18997109 [patent_doc_number] => 11913945 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Method for determining the amount of a therapeutic antibody in the brain [patent_app_type] => utility [patent_app_number] => 17/136289 [patent_app_country] => US [patent_app_date] => 2020-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 27510 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 395 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17136289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762416 [patent_doc_number] => 20210107997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => ANTIBODY WITH NON-NATURAL AMINO ACID INTRODUCED THEREIN [patent_app_type] => utility [patent_app_number] => 17/131135 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17131135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778079 [patent_doc_number] => 20210115157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => COVALENT HETEROBIVALENT ANTIBODY INHIBITORS AND LIGANDS [patent_app_type] => utility [patent_app_number] => 17/126466 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 437 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18177644 [patent_doc_number] => 20230038373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => STABILE CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/783738 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962941 [patent_doc_number] => 20210214440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => MATERIALS AND METHODS FOR IN VIVO BIOLOGICAL TARGETING [patent_app_type] => utility [patent_app_number] => 17/125162 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 140054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208200 [patent_doc_number] => 20230054458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/782980 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782980 [rel_patent_id] =>[rel_patent_doc_number] =>)